Advertisement

Impact of epidermal growth factor receptor, mesenchymal–epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer

Published:August 13, 2012DOI:https://doi.org/10.1016/j.bjoms.2012.06.009

      Abstract

      The aim of this study was to evaluate the impact of expression of epidermal growth factor receptor (EGFR), mesenchymal–epithelial transition factor (c-Met), and insulin-like growth factor receptor 1 (IGF-1R) protein on response to treatment and survival in patients with oral and oropharyngeal squamous cell carcinoma (SCC). EGFR, c-Met, and IGF-1R immunohistochemical (IHC) scores were generated based on the incidence and intensity of expression of the biomarkers evaluated in paraffin-embedded sections of biopsy specimens taken before treatment from 113 patients given neoadjuvant chemoradiotherapy followed by resection for primary locally advanced oral and oropharyngeal SCC. Correlations were assessed between the IHC of the biomarkers and the patients’ clinicopathological variables using Spearman's rank test. Cox's regression models were used to evaluate the impact of EGFR, c-Met, and IGF-1R, expression on survival.
      Almost all the patients showed expression of EGFR, c-Met, and IGF-1R (99%, 100%, and 100%, respectively). None of the biomarkers examined predicted response to neoadjuvant chemoradiotherapy or were associated with survival. In multivariate analysis, age (p = 0.05), alcohol consumption (p = 0.03), and pathological size/extent of the primary tumour after neoadjuvant treatment (ypT) status (p = 0.009) were significantly associated with recurrence-free survival. Age (p = 0.02) and alcohol consumption (p = 0.02) were independently associated with overall survival. Although none of the biomarkers evaluated could be used as prognostic indicators, their common expression suggested a strong rationale for targeting EGFR, c-Met, and IGF-1R in the treatment of oral and oropharyngeal SCC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sargeran K.
        • Murtomaa H.
        • Safavi S.M.
        • Vehkalahti M.M.
        • Teronen O.
        Survival after diagnosis of cancer of the oral cavity.
        British Journal of Oral and Maxillofacial Surgery. 2008; 46: 187-191
        • Cohen E.E.
        Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
        Journal of Clinical Oncology. 2006; 24: 2659-2665
        • Mayor S.
        MET inhibitors: translating from bench to bedside.
        Lancet Oncology. 2011; 12: 14
        • Baserga R.
        • Peruzzi F.
        • Reiss K.
        The IGF-1 receptor in cancer biology.
        International Journal of Cancer. 2003; 107: 873-877
        • Ciardiello F.
        • Tortora G.
        Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.
        European Journal of Cancer. 2003; 39: 1348-1354
        • Lopez T.
        • Hanahan D.
        Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis.
        Cancer Cell. 2002; 1: 339-353
        • Birchmeier C.
        • Birchmeier W.
        • Gherardi E.
        • Vande Woude G.F.
        Met, metastasis, motility and more.
        Nature Reviews Molecular Cell Biology. 2003; 4: 915-925
        • Karamouzis M.V.
        • Konstantinopoulos P.A.
        • Papavassiliou A.G.
        Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
        Lancet Oncology. 2009; 10: 709-717
        • van der Veeken J.
        • Oliveira S.
        • Schiffelers R.M.
        • Storm G.
        • van Bergen En Henegouwen P.M.
        • Roovers R.C.
        Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
        Current Cancer Drug Targets. 2009; 9: 748-760
        • Rubin Grandis J.
        • Melhem M.F.
        • Gooding W.E.
        • Day R.
        • Holst V.A.
        • Wagener M.M.
        • et al.
        Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.
        Journal of the National Cancer Institute. 1998; 90: 824-832
        • Kim C.H.
        • Koh Y.W.
        • Han J.H.
        • Kim J.W.
        • Lee J.S.
        • Baek S.J.
        • et al.
        c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma.
        Head and Neck. 2010; 32: 1655-1664
        • Lo Muzio L.
        • Leonardi R.
        • Mignogna M.D.
        • Pannone G.
        • Rubini C.
        • Pieramici T.
        • et al.
        Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma.
        Anticancer Research. 2004; 24: 1063-1069
        • Lara P.C.
        • Bordon E.
        • Rey A.
        • Moreno M.
        • Lloret M.
        • Henriquez-Hernandez L.A.
        IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma.
        Oral Oncology. 2011; 47: 615-619
        • Braun O.M.
        • Neumeister B.
        • Popp W.
        • Scherrer R.
        • Dobrowsky E.
        • Dobrowsky W.
        • et al.
        Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
        Cancer. 1989; 63: 1097-1100
        • Perisanidis C.
        • Perisanidis B.
        • Wrba F.
        • Brandstetter A.
        • El Gazzar S.
        • Papadogeorgakis N.
        • et al.
        Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.
        Journal of Oral Pathology and Medicine. 2012; 41: 40-46
        • Pirker R.
        • Pereira J.R.
        • von Pawel J.
        • Krzakowski M.
        • Ramlau R.
        • Park K.
        • et al.
        EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
        Lancet Oncology. 2012; 13: 33-42
        • Kalyankrishna S.
        • Rubin Grandis J.
        Epidermal growth factor receptor biology in head and neck cancer.
        Journal of Clinical Oncology. 2006; 24: 2666-2672
        • Seiwert T.Y.
        • Jagadeeswaran R.
        • Faoro L.
        • Janamanchi V.
        • Nallasura V.
        • El Dinali M.
        • et al.
        The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
        Cancer Research. 2009; 69: 3021-3031
        • Yuan Y.
        • Zhou X.
        • Song J.
        • Qiu X.
        • Li J.
        • Ye L.
        • et al.
        Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma.
        Annals of Otology, Rhinology and Laryngology. 2008; 117: 192-200
        • Rubin Grandis J.
        • Melhem M.F.
        • Barnes E.L.
        • Tweardy D.J.
        Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck.
        Cancer. 1996; 78: 1284-1292
        • Nakata Y.
        • Uzawa N.
        • Takahashi K.
        • Sumino J.
        • Michikawa C.
        • Sato H.
        • et al.
        EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas.
        European Journal of Cancer. 2011; 47: 2364-2372
        • Bentzen S.M.
        • Atasoy B.M.
        • Daley F.M.
        • Dische S.
        • Richman P.I.
        • Saunders M.I.
        • et al.
        Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
        Journal of Clinical Oncology. 2005; 23: 5560-5567
        • Xu H.
        • Stabile L.P.
        • Gubish C.T.
        • Gooding W.E.
        • Rubin Grandis J.
        • Siegfried J.M.
        Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
        Clinical Cancer Research. 2011; 17: 4425-4438
        • Jameson M.J.
        • Beckler A.D.
        • Taniguchi L.E.
        • Allak A.
        • Vanwagner L.B.
        • Lee N.G.
        • et al.
        Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
        Molecular Cancer Therapeutics. 2011; 10: 2124-2134
      1. National Institutes of Health. Clinical trials registry. Identifier: NCT00957853. Available at: <http://www.clinicaltrials.gov>.